We are live on ! Find out more
HRMY icon

Harmony Biosciences
HRMY

204 hedge funds and large institutions have $1.62B invested in Harmony Biosciences in 2023 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 86 increasing their positions, 56 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more call options, than puts

Call options by funds: $9.47M | Put options by funds: $4.32M

54% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 56

3% less funds holding

Funds holding: 211 → 204 (-7)

4.31% less ownership

Funds ownership: 86.69% → 82.38% (-4.3%)

11% less capital invested

Capital invested by funds: $1.83B → $1.62B (-$205M)

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

18% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 39

Holders
204
Holders Change
-7
Holders Change %
-3.32%
% of All Funds
3.24%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.1%
New
32
Increased
86
Reduced
56
Closed
39
Calls
$9.47M
Puts
$4.32M
Net Calls
+$5.15M
Net Calls Change
+$9.9M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$13.3M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$7.64M
3
PA
Perceptive Advisors
New York
+$3.64M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.07M
5
State Street
State Street
Massachusetts
+$3M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$19.4M
2
Pacer Advisors
Pacer Advisors
Pennsylvania
-$15.2M
3
Millennium Management
Millennium Management
New York
-$13.3M
4
Man Group
Man Group
United Kingdom
-$11.1M
5
American Century Companies
American Century Companies
Missouri
-$9.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
VM
1
Valor Management
Illinois
$368M – – –
BlackRock
2
BlackRock
New York
$201M +$13.3M +382,009 +7%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$179M -$696K -20,038 -0.4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$121M +$3.07M +88,295 +2%
VC
5
Vivo Capital
California
$85.4M – – –
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$46.5M +$7.64M +220,000 +18%
State Street
7
State Street
Massachusetts
$40.2M +$3M +86,527 +8%
VP
8
venBio Partners
California
$33.9M – – –
PA
9
Perceptive Advisors
New York
$32.6M +$3.64M +104,936 +12%
Macquarie Group
10
Macquarie Group
Australia
$31.2M +$1.77M +50,865 +6%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$25.7M +$1.8M +51,893 +7%
Morgan Stanley
12
Morgan Stanley
New York
$24.8M +$883K +25,421 +3%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$23.6M +$2.02M +58,070 +9%
NPIC
14
Neumeier Poma Investment Counsel
California
$19.5M -$1.41M -40,750 -6%
Aberdeen Group
15
Aberdeen Group
United Kingdom
$19.1M -$2.17M -62,604 -10%
Massachusetts Financial Services
16
Massachusetts Financial Services
Massachusetts
$16.7M +$30K +864 +0.2%
N
17
Nuveen
North Carolina
$15.9M +$2.74K +79 +0%
ACM
18
Ashford Capital Management
Delaware
$14.2M -$517K -14,890 -3%
NFGH
19
Nan Fung Group Holdings
Hong Kong
$12.1M – – –
6CM
20
683 Capital Management
New York
$11.5M +$1.74M +50,000 +17%
Northern Trust
21
Northern Trust
Illinois
$11.3M +$418K +12,027 +4%
HRCM
22
Hood River Capital Management
Florida
$10.4M +$194K +5,587 +2%
IBT
23
International Biotechnology Trust
United Kingdom
$10.3M -$8.89M -256,000 -45%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$9.57M -$3.84M -110,700 -27%
Renaissance Technologies
25
Renaissance Technologies
New York
$9.57M -$4.11M -118,300 -29%
1
2 3 4 5

HRMY Hedge Fund Activity: Q3 2023 in Review

204 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q3 2023, worth a combined $1.62B — down 11% from $1.83B a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of HRMY and 32 opened new positions — a net loss of 7 holders — while 56 trimmed existing stakes and 86 added.

The largest buyer was BlackRock, adding an estimated $13.3M. The largest seller was Citadel Advisors, cutting an estimated $19.4M.

  • 204 institutional investors held Harmony Biosciences (HRMY) as of Q3 2023, down from 211 in Q2 2023.
  • Funds reported $1.62B of Harmony Biosciences stock for Q3 2023, down 11% quarter-over-quarter.
  • 32 funds opened new Harmony Biosciences positions in Q3 2023 and 39 closed out, a net change of -7 holders.
  • The largest Harmony Biosciences buyer in Q3 2023 was BlackRock, an estimated $13.3M added.
  • The largest Harmony Biosciences seller in Q3 2023 was Citadel Advisors, an estimated $19.4M sold.

Based on aggregated 13F filings for Q3 2023.